Snibe's Clinical Chemistry Analysis System Receives CDC Certification

On June 16, the Total Glycerides (TG) assay on Snibe's clinical chemistry analysis system successfully passed the CDC-CRMLN certification. This certification demonstrates that the assay meets the performance standards specified by the U.S. NCEP and is traceable to international reference methods. It once again validates that Snibe's clinical chemistry analysis platform consistently meets internationally recognized standards.

BGI Ranks First Globally Among Bioscience Industry Institutions

On June 11, the 2026 Nature Index Annual Tables were officially released, bringing another milestone for BGI. This authoritative ranking, which measures top-tier global academic output, named BGI as the world's No. 1 bioscience industry institution.

Furthermore, according to previously published Nature Index tables, BGI has now maintained the top position among bioscience industry institutions in the Asia-Pacific region for 11 consecutive years.

Dirui Medical Supports Boao Yiling Laboratory in Achieving ISO15189 International Accreditation for the Third Time

Recently, the Clinical Laboratory of Boao Yiling Life Care Center successfully completed the on-site reassessment for ISO15189 medical laboratory accreditation, passing all items with high standards and successfully retaining its internationally recognized laboratory qualification. As a long-term equipment and technical service provider, Dirui Medical has served as a critical hardware backbone for the laboratory's implementation of the ISO15189 quality control system, leveraging its self-developed testing instruments across multiple series and comprehensive full-process technical support services.

Fosun Adgenvax Raises RMB 968 Million in New Financing, Plans Hong Kong IPO

On June 16, Fosun Pharma announced that its controlling subsidiary, Fosun Adgenvax, plans to increase its share capital through a private placement at RMB 84.21 per share. The company will issue a total of 11.4954 million new shares, accounting for approximately 12.15% of the post-increase total share capital, to four investors, raising a total of RMB 968 million.